FDA Grants Daridorexant Breakthrough Status for Pediatric Insomnia
Idorsia's dual orexin receptor antagonist received the designation based on a phase 2 trial in children and adolescents with insomnia disorder.
Updated on Nov. 4, 2026 in Sleep Disorders
The FDA granted Breakthrough Therapy designation to daridorexant for pediatric insomnia disorder, a move the company announced on November 4, 2026. The designation is supported by a phase 2 dose-finding trial that showed a dose-dependent improvement in objective total sleep time.
Why it matters
The designation reflects significant unmet medical need among children and adolescents living with insomnia disorder, a population with few approved treatment options. It signals regulatory support for accelerating development of a drug for young patients.
A randomized phase 2 trial enrolled 165 patients aged 10 to under 18, where 50mg daridorexant increased objective total sleep time by 50 minutes versus 20 minutes with placebo (P=.0185 for dose-dependent improvement). Phase 3 requirements remain under discussion with the FDA, and long-term safety in this age group has not been established.
The players
Idorsia
Idorsia is a Swiss pharmaceutical company that developed daridorexant, a dual orexin receptor antagonist approved for adult insomnia.
U.S. Food and Drug Administration (FDA)
The FDA is the U.S. federal agency responsible for regulating drugs, and it granted the Breakthrough Therapy designation.
The details
Participants were randomly assigned 1:1:1:1 to daridorexant 10mg, 25mg, 50mg, or placebo taken once daily in the evening. The primary endpoint was change from baseline to day 1 in objective total sleep time, with secondary improvements seen in sleep quality, morning alertness, and daytime functioning.
Timeline
October 23, 2026: Idorsia presented pediatric and adult daridorexant results at Sleep Europe 2026.
November 4, 2026: FDA Breakthrough Therapy designation for pediatric insomnia was announced.
Drug Class Context
Daridorexant belongs to the dual orexin receptor antagonist class, which also includes suvorexant, and both act by blocking the wake-promoting orexin signaling pathway. The pediatric designation extends a class whose approvals and trials have so far centered on adult patients.
Parents of children with persistent insomnia may eventually have a prescription option designed for their age group, though approval is not yet granted. Families should continue to discuss current sleep concerns with a pediatrician, since no pediatric indication exists yet.
The takeaway
Pediatric sleep medicine has few approved options, so this designation is a meaningful signal for young patients. Families dealing with ongoing sleep problems should raise them with a clinician rather than waiting for a new drug.
Further reading
For broader background on treatments for children and adults, see Sleep Disorders.
Source note: This article includes information reported by Neurology Advisor.
